United Therapeutics to Present Innovations at J.P. Morgan Healthcare Conference 2025

United Therapeutics Prepares to Showcase Innovations at J.P. Morgan Healthcare Conference

United Therapeutics Corporation, a leader in innovative pharmaceutical therapies focused on addressing critical medical needs, announces that Dr. Martine Rothblatt, its Chairperson and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference. Scheduled for January 13, 2025, from 2:15 p.m. to 2:55 p.m. Pacific Standard Time, the presentation will take place in San Francisco and will be available via live webcast on the company’s website. Following the event, an archived version will remain accessible for 30 days, ensuring that stakeholders and interested parties can engage with the insights shared during the conference.

United Therapeutics stands out not only for its innovative therapies but also for its commitment to the public benefit corporation model, making it the first publicly traded biotech or pharmaceutical company to adopt this structure. This approach underscores the company's mission to create a brighter future for patients by enhancing the availability of transplantable organs and addressing unmet medical needs. The emphasis on public benefit reflects United Therapeutics' dedication to social responsibility, prioritizing patient outcomes while simultaneously benefiting its stakeholders through ethical business practices and corporate transparency.

The upcoming presentation is expected to highlight United Therapeutics' ongoing efforts to revolutionize patient care through creativity, enthusiasm, and bold innovation. The company is known for its forward-thinking strategies and has developed numerous therapies that significantly impact the lives of patients with rare conditions. As the healthcare landscape evolves, United Therapeutics remains committed to advancing medical technology and ensuring that patients have access to life-saving treatments.

In addition to its focus on innovation and patient care, United Therapeutics actively engages in communication with its stakeholders through periodic updates and disclosures. The company includes forward-looking statements in its reports to the Securities and Exchange Commission, providing insights into its strategic direction while recognizing potential risks. This commitment to transparency is essential for maintaining stakeholder confidence and fostering an environment of trust in its mission.

As United Therapeutics prepares for the J.P. Morgan Healthcare Conference, the anticipation surrounding its presentation reflects the broader industry interest in companies that prioritize both innovation and public benefit. With a unique corporate identity and a clear vision for the future, United Therapeutics continues to exemplify how biotechnology can serve the dual purpose of advancing medical science while contributing positively to society.